Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma

Active:	Yes
Cancer Type:	Hematopoietic Malignancies Lymphoma Non-Hodgkin Lymphoma Unknown Primary	NCT ID:	NCT04989803
Trial Phases:	Phase I Phase II	Protocol IDs:	KT-US-499-0150 (primary) NCI-2021-10014 2020-000562-41
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Kite, A Gilead Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT04989803

Summary

The goal of this clinical study is to learn more about the safety and effectiveness of
the study drugs, KITE-363 and KITE-753, in participants with relapsed and/or refractory
B-cell lymphoma.

Objectives

Eligible study participants who have received IP administration with either KITE-363 or
KITE-753 will transition to a separate Long-term Follow-up study (Study KT-US-982-5968)
to complete the remainder of the 15-year follow-up assessments.

Treatment Sites in Georgia

Northside Hospital Cancer Institute - Bone Marrow Transplant (BMT)
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-851-8523

Doctors:

Lizamarie Bachier

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.